Evidence map›Paper›PMID 28161932›Full record

ArticleCancer research and treatment2017

Survival of Cancer Patients in Northeast China: Analysis of Sampled Cancers from Population-Based Cancer Registries.

Yanxia Li, Liya Yu, Jun Na, Shuang Li, Li Liu, Huijuan Mu, Xuanjuan Bi, Xiaoxia An, Xun Li, Wen Dong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yanxia LiInstitute of Chronic Disease, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China.
Liya YuInstitute of Chronic Disease, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China.
Jun NaInstitute of Chronic Disease, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China.
Shuang LiInstitute of Chronic Disease, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China.
Li LiuInstitute of Chronic Disease, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China.
Huijuan MuInstitute of Chronic Disease, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China.
Xuanjuan BiInstitute of Chronic Disease, Anshan Municipal Center for Disease Control and Prevention, Anshan, China.
Xiaoxia AnInstitute of Chronic Disease, Benxi Municipal Center for Disease Control and Prevention, Benxi, China.
Xun LiInstitute of Chronic Disease, Shenyang Municipal Center for Disease Control and Prevention, Shenyang, China.
Wen DongDepartment of Personal Resource, Dalian Medical University, Dalian, China.
Guowei PanInstitute of Chronic Disease, Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe cancer survival was characterized by following up sampled subgroups of cancer cases from three population-based cancer registries in Northeast China. MATERIALS AND

methodsSurvival analysis was used to analyze 6,871 patients, who had one of the 21 most common cancers based on sampling from the population-based cancer registries of three cities in Liaoning Province. All patients were diagnosed between 2000 and 2002 and were followed up to the end of 2007 by active and passive methods. The 5-year age standardized relative survival rates (ASRS) were estimated for all cancers combined and each of the 21 individual cancers.

resultsThe survival status was traced for 80.8% of 8,506 sampled cancer cases. The 5-year ASRS for all 21 cancers combined was 41.5% (95% confidence interval, 40.3 to 42.7), the highest ASRS was observed for thyroid cancer (85.2%), breast cancer (78.9%), uterine corpus cancer (75.9%), and urinary bladder cancer (70.2%); the lowest 5-year ASRS was noted in pancreatic cancer (8.8%), liver cancer (11.0%), esophageal cancer (18.8), and lung cancer (19.6%). The cancer survival rates in Liaoning cities were similar to those of urban areas in mainland China, but significantly lower than those in Hong Kong, Korea, and Japan.

conclusionThe strikingly poor cancer survival rates in three cities of Liaoning Province and in other places in China highlight the need for urgent investment in cancer prevention, early detection, and standardized and centralized treatment.

Indexed as

Age DistributionChinaFemaleFollow-Up StudiesHumansMaleNeoplasmsPopulation SurveillanceRegistriesSurvival AnalysisCancer registryChinaNeoplasmsPopulation-based studySurvival rate

Identifiers

PMID28161932
PMCPMC5654172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.